RUNX1 and acute lymphoblastic leukemia: This excellent outcome differs from 22 and 13% 5-year cumulative incidence of relapse reported for 18 ETV6::RUNX1-like-ALL cases treated on Total Therapy 16 (n = 9) [42] or MS2003/2010 (n = 9) [41], respectively.